Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.


The present paper demonstrates that the proteasome inhibitor bortezomib, which behaves as an apoptotic agent in hepatoma HepG2 cells, caused in these cells a decrease in IkappaBalpha level and a consequent increase in NF-kappaB activity. The effect already appeared at 4 h of treatment and preceded the onset of apoptosis which was observed at 24 h. Our… (More)


  • Presentations referencing similar topics